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ABSTRACT
Macroautophagy/autophagy inhibition is a novel anticancer therapeutic strategy, especially for tumors
driven by mutant RAS. Here, we demonstrate that autophagy inhibition in RAS-mutated cells induces
epithelial-mesenchymal transition (EMT), which is associated with enhanced tumor invasion. This is at
least partially achieved by triggering the NFKB/NF-κB pathway via SQSTM1/p62. Knockdown of ATG3 or
ATG5 increases oncogenic RAS-induced expression of ZEB1 and SNAI2/Snail2, and activates NFKB
activity. Depletion of SQSTM1 abolishes the activation of the NFKB pathway induced by autophagy
inhibition in RAS-mutated cells. NFKB pathway inhibition by depletion of RELA/p65 blocks this EMT
induction. Finally, accumulation of SQSTM1 protein correlates with loss of CDH1/E-cadherin expression
in pancreatic adenocarcinoma. Together, we suggest that combining autophagy inhibition with NFKB
inhibitors may therefore be necessary to treat RAS-mutated cancer.
Abbreviations: 4-OHT: 4-hydroxytamoxifen; DIC: differential interference contrast; EMT: epithelial-
mesenchymal transition; ESR: estrogen receptor; MAPK/ERK: mitogen-activated protein kinase; iBMK:
immortalized baby mouse kidney epithelial cells; MET: mesenchymal-epithelial transition; PI3K: phos-
phoinositide 3-kinase; RNAi: RNA interference; TGFB/TGF-β: transforming growth factor beta; TNF: tumor
necrosis factor; TRAF6: TNF receptor associated factor 6.
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Autophagy is an evolutionarily conserved biological process
that degrades long-lived proteins and cytoplasmic organelles.
The manipulation of autophagy has emerged as a new ther-
apeutic strategy with which to treat neurodegenerative dis-
eases and cancer [1–3]. Autophagy has a double-edged sword
effect in cancer [2,3]. Autophagy’s tumor suppressive function
is partly attributed to its ability to induce cell death via several
mechanisms [4,5]; however, a positive role of autophagy in
tumorigenesis has also been established. Emerging studies
have shown that the RAS signalling pathway is one of the
oncogenic pathways influenced by autophagic activity [6–12].
Oncogenic RAS mutations, which activate both the RAF-
MAPK/ERK (mitogen-activated protein kinase) and phos-
phoinositide 3-kinase (PI3K)-AKT signalling pathways, are
among the most prevalent genetic changes found in human
cancers, occurring in approximately 20% of human tumors
[13,14]. The mutation rate of RAS varies depending on tumor
type, with KRAS mutations occurring in over 90% of
pancreatic carcinomas and 30–50% of colorectal cancer.
Yang and colleagues demonstrated that the inhibition of
autophagy in pancreatic tumor cells suppressed their growth
by reducing the production of reactive oxygen species, thus
limiting effective metabolism via decreased mitochondrial
oxidative phosphorylation and increased DNA damage [8].
This finding provides an example of a positive role of autop-
hagy in pancreatic tumorigenesis [8]. Accordingly, there are
several phase I/II clinical trials in progress using the autop-
hagy inhibitors chloroquine or hydroxychloroquine in combi-
nation with chemotherapy for the treatment of a range of
tumors, including pancreatic cancer [15].
Although the rationale for such studies is supported by
strong preclinical data, many open questions and controver-
sies remain regarding autophagy as a target in cancer therapy
[16]. Some potential caveats associated with autophagy inhi-
bition in cancer therapy warrant consideration. There are
concerns about whether autophagy inhibition treatment may
increase the incidence of tumor invasion and metastasis. In
order to invade, disseminate to distant tissues and
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subsequently form metastatic colonies, neoplastic epithelial
cells, which exhibit predominantly epithelial cancer cell phe-
notype, must shift, at least transiently, into a more mesench-
ymal cancer cell phenotype. This shift is achieved by the
activation of the complex cell-biological program termed the
epithelial-mesenchymal transition (EMT) [17], which is
a cellular reprogramming process that is mainly induced by
a number of transcription factors, such as SNAIs/Snails,
TWISTs and ZEBs, that bind E-boxes in the proximal pro-
moter of the CDH1/E-cadherin gene and repress its expres-
sion [18]. Currently, there are controversial reports available
regarding the effect of autophagy on the regulation of EMT
[19], and it is likely dependent on the cellular type and/or on
stage of tumor progression.
Several works show that defects in the autophagic machin-
ery restrain dissemination and metastatic spreading of cancer
[20–22]. In line with these facts, inhibition of autophagy
reduces FSTL1 (follistatin like 1)-induced EMT in human
bronchial epithelial cells [23], whereas ATG4A overexpression
significantly promotes EMT in gastric cancer cells [24].
Conversely, there is evidence indicating that autophagy acts
to prevent EMT and that the activation of the autophagic
machinery may determine reversion of the EMT phenotype
in cancer cells [25–34]. Thus, understanding the factors that
determine the effect of autophagy on EMT is crucial before we
apply autophagy inhibitors or inducers to treat cancer
patients. Here, we report that autophagy inhibition specifically
promotes EMT and invasion in RAS-mutated cancer cells, but
not in RAS wild-type cells. This is achieved, at least partially,
by an elevation in SQSTM1/p62 expression that induces
RELA/p65 mediated-transactivation of EMT transcription
factors such as ZEB1 and SNAI2/Snail2.
Results
Autophagy inhibition specifically activates the EMT
program in RAS-mutated cancer cells
To investigate whether RAS mutational status influences the
effect of autophagy in regulating EMT, we used RNA inter-
ference (RNAi) to deplete ATG5, an important component of
the autophagic machinery, in 7 human cancer cell lines
derived from the pancreas (PaCa3, Suit-2, PANC1 and
MDA Panc3) and colon (HCT116, HKe3 and HKh2). Four
of these cancer cell lines express mutant KRAS (Suit-2,
PANC1, MDA Panc3 and HCT116) [35], whereas PaCa3,
HKe3 and HKh2 lines express wild-type RAS. ATG5 depletion
led to a clear reduction in CDH1 protein and mRNA expres-
sion in all cancer cell lines that express mutant KRAS, includ-
ing Suit-2 (KRAS G12D), PANC1 (KRAS G12D), MDA Panc3
(KRAS G12A), and HCT116 (KRAS G13D) (Figure 1(a, b);
Figure S1(a, b). Remarkably, under the same conditions,
ATG5 knockdown had no effect on CDH1 expression in all
3 wild-type RAS expressing cell lines, including PaCa3, HKe3
and HKh2 (Figure 1(a, b); Figure S1(a)). Importantly, the
HKe3 and HKh2 lines are isogenic counterparts of HCT116,
in which the allele of KRAS G13D is disrupted by homologous
recombination [35]. Thus, there is only one allele of wild-type
KRAS in the HKe3 and HKh2 lines.
EMT is a cellular reprogramming process that is mainly
induced by a number of transcription factors, such as SNAI1/
Snail1, SNAI2, TWIST1, ZEB1 and ZEB2, which bind E-boxes
in the proximal promoter of the CDH1 gene to repress its
expression [18]. We thus investigated the impact of ATG5
RNAi on the expression levels of EMT transcription factors in
the same panel of cancer cell lines. In wild-type RAS-
expressing PaCa3 cells, there were no significant inductions
of EMT transcription factors (Figure 1(b)). However, in the
cells with mutant RAS, the EMT transcription factors were
induced with different expression patterns. Following ATG5
depletion, we observed upregulation of ZEB1 and SNAI2 in
Suit-2 and HCT116, upregulation of SNAI2 in PANC1, and
upregulation of ZEB1 and ZEB2 in MDA Panc3 (Figure 1(b);
Figure S1(b)).
When grown in nude mice, nontumorigenic baby mouse
kidney epithelial (iBMK) cells transduced with HRas V12 form
tumors [10]. Although, as shown previously [10], oncogenic RAS-
expressing atg5−/- or atg7−/- cells display reduced tumor growth,
we found that CDH1 expression was largely reduced in oncogenic
RAS-expressing atg7−/- or atg5−/- tumors compared to oncogenic
RAS-expressing Atg7+/+ or Atg5+/+ tumors (Figure 1(c); Figure S1
(c)). These data suggest that EMT is induced in autophagy-
deficient RAS-mutated tumors in vivo.
Together, these results demonstrate that autophagy inhibi-
tion is able to activate the EMT program, specifically in RAS-
mutated cancer cells, which is supported by the induction of
EMT transcription factors and, consequently, a reduction in
CDH1 expression.
Autophagy inhibition cooperates with RAS activation to
induce EMT
To further confirm the observation above, we utilized the estab-
lished RAS-induced EMT model [36,37]. HKe3 ER:HRAS V12
cells were generated by introducing a regulatable RAS construct
into HKe3 cells comprising mutant HRAS fused to the ESR
(estrogen receptor) ligand-binding domain that is conditionally
responsive to 4-hydroxytamoxifen (OHT). Addition of 4-OHT
acutely activates the RAS pathway in HKe-3 cells expressing ER:
HRAS V12 and induces EMT [36,37].
Oncogenic RAS activation induced autophagic activity, as
demonstrated by MAP1LC3/LC3 puncta staining
(Figure 2(a)) and an increase in LC3-II by western blot ana-
lysis (Fig. S2A). Knockdown of ATG5 blocked the autophagic
activation induced by oncogenic RAS (Figure 2(a); Figure S2
(a)). We have shown previously that oncogenic RAS activation
leads to EMT in these cells [36,37] (Figure 2). Interestingly,
ATG5 knockdown together with oncogenic RAS activation
achieved a synergistic effect in inducing EMT, reflected by
a larger increase in ZEB1 expression and a further reduction
in CDH1 levels, as well as a replacement of cortical actin
filaments by actin stress fibers and a scattered cellular pheno-
type (Figure 2(a), 4-OHT group; Figure 2(b)). As aforemen-
tioned (Figure 1(a, b)), depletion of ATG5 in wild-type RAS
cells did not significantly induce EMT (Figure 2(a), control
group; Figure 2(b)), confirming that autophagy inhibition
specifically promotes mutant RAS-induced EMT.
AUTOPHAGY 887
Figure 1. Autophagy inhibition promotes EMT in RAS-mutated cells. (a) Protein expression of CDH1 and ATG12–ATG5 in the indicated pancreatic cancer cell lines transfected
with control siRNA or ATG5 siRNA. TUBB/β1-tubulin was used as a loading control. For protein expression of CDH1 and ATG12–ATG5 in pancreatic cancer cell lines with mutant
KRAS, both short and long exposures (respectively) are shown. KRASmutation status is indicated under the blots. (b) Fold change in mRNA levels of CDH1, SNAI1, SNAI2, TWIST1,
ZEB1 and ZEB2 in the indicated pancreatic cancer cell lines transfected with control siRNA or ATG5 siRNA. GAPDH-normalized mRNA levels in control cells were used to set the
baseline value at unity. Data are mean ± s.d. n = 3 samples per group. * P < 0.05. ** P < 0.01. *** P < 0.001. (c) Immunofluorescence staining of CDH1 (green) in HRas V12-
expressing Atg7+/+ tumors orHRas V12-expressing atg7−/- tumors. TO-PRO-3 (blue) was used to stain nucleic acids. Scale bar: 20 μm. Atg7+/+ or atg7−/- iBMK cells transducedwith
HRas V12were subcutaneously injected in nudemice to form tumors. The graph shows the average relative intensity of CDH1 per cell evaluated using ImageJ, and data aremean
± s.d. n = 4 random fields. *** P < 0.001.
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Figure 2. Autophagy inhibition promotes oncogenic RAS-induced EMT. (a) Immunofluorescence staining of LC3 (green), CDH1 (green), ZEB1 (red) or F-actin in HKe3 ER:HRASV12
cells with the indicated treatments. Rhodamine-phalloidin was used to stain F-actin. TO-PRO-3 (blue) was used to stain nucleic acids. Scale bar: 20μm. (b) Protein expression of
CDH1, ZEB1, SNAI2, SNAI1, ZEB2, TWIST1, ATG12–ATG5 and phospho-MAPK/ERK (p-MAPK) in HKe3 ER:HRAS V12 cells with the indicated treatments. TUBBwas used as a loading
control. (c) Fold change inmRNA levels of CDH1, ZEB1 and SNAI2 in HKe3 ER:HRAS V12 cells with the indicated treatments.mRNA levels normalized to ACTB/β-actin in control cells
were used to set the baseline value at unity. Data are mean ± s.d. n = 3 samples per group. n.s. P > 0.05, *** P < 0.001. (d) Protein expression of CDH1, ZEB1, SNAI2 and ATG12–
ATG5 in 4-OHT-treated HKe3 ER:HRAS V12 cells with the indicated treatments. TUBB was used as a loading control.
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To eliminate the autophagy-independent effect of ATG5,
we also inhibited autophagic activity by depletion of another
key component in the autophagic machinery, ATG3.
Knockdown of ATG3 or ATG5 blocked oncogenic RAS-
induced autophagy, as measured by the overall level of LC3-
II (Fig. S2A). ATG5 or ATG3 knockdown alone in HKe3 ER:
HRAS V12 cells slightly increased the mRNA levels of ZEB1
and SNAI2. The addition of 4-OHT to activate mutant RAS in
HKe3 ER:HRAS V12 cells led to a 10-fold increase of ZEB1
mRNA levels and a 20-fold increase of SNAI2 mRNA, which
is consistent with our previous report [36,37]. Most strikingly,
ATG5 or ATG3 knockdown together with oncogenic RAS
activation achieved a synergistic effect in inducing EMT,
reflected by a larger increase in ZEB1, SNAI2 and VIM
(vimentin) expression, and a further downregulation of
CDH1 (Figure 2(b, c); Figure S2). ATG5 depletion in 4-OHT-
treated HKe3 ER:HRAS V12 cells induced a 20-fold increase
in ZEB1 mRNA, an 80-fold increase in SNAI2 mRNA and
a 40-fold increase in VIM mRNA; while ATG3 depletion in
RAS-activated cells induced a 30-fold increase in ZEB1
mRNA, a 120-fold increase in SNAI2 mRNA and a 40-fold
increase in VIM mRNA (Fig. S2B). However, the effects on
SNAI1, ZEB2 and TWIST1 were minimal (Figure 2(b); Figure
S2(b)). In addition, ZEB1 RNAi or SNAI2 RNAi alone
induced a small but detectable increase of CDH1 protein
level in ATG5-depleted HKe3–ER:HRASV12 cells treated
with 4-OHT (Figure 2(d)). Double knockdown of SNAI2
and ZEB1 achieved an additive effect, reflected by a larger
increase in CDH1 expression than that observed in cells
treated with SNAI2 or ZEB1 RNAi alone (Figure 2(d)).
These data suggest that autophagy inhibition specifically pro-
motes EMT in RAS-mutated cells, mainly via upregulation of
ZEB1 and to a lesser extent via SNAI2.
EMT can also be induced by several extracellular cues in
the microenvironment of a given epithelial tissue, such as
TGFB/TGF-β (transforming growth factor beta) [38]. We
found autophagy inhibition via RNAi-mediated depletion of
ATG5 or ATG3 did not promote TGFB-induced EMT in
HaCat cells (Fig. S3A). We further tested this with another
ER:HRAS V12 system in an immortalized human breast
epithelial cell line, MCF10A. ATG5 knockdown together
with oncogenic RAS activation, but not TGFB, achieved
a synergistic effect in inducing EMT, reflected by a further
reduction in CDH1 levels (Fig. S3B). These data indicate that
autophagy inhibition specifically promotes RAS-induced, but
not TGFB-induced EMT.
Autophagy inhibition cooperates with RAS activation to
promote cell migration and to induce invasion
The EMT process allows epithelial cells to detach from the
primary site and invade surrounding tissues in order to
migrate to and colonize a new site [17]. ATG5’s ability to
affect cell mobility was tested using a wound scratch assay.
Twenty-four h after the scratch wound, ATG5 RNAi-
transfected 4-OHT-treated HKe3 ER:HRAS V12 cells filled
all the gaps, whereas the wound in the control cells was still
open (Figure 3(a, b); Fig. S4A). However, under the same
conditions, ATG5 knockdown had no effect on cell migration
in control HKe3 ER:HRAS V12 cells, in which mutant RAS is
not activated (Figure 3(b)). In addition, we stably expressed
control or ATG5 shRNA in HCT116 cells that have mutated
KRAS G13D (Fig. S4B). In the Transwell migration and
Matrigel invasion assays, ATG5 shRNA promoted both cell
migration and invasion in HCT116 cells (Figure 3(c, d)).
To further investigate whether autophagy inhibition coop-
erates with RAS activation to induce invasion, we tested this
with MCF10A ER:HRAS V12 cells, which form highly polar-
ized epithelial acini (3D culture model) when grown on
a thick layer of Matrigel. This system is used extensively to
study invasion and pathways that can perturb the breast
epithelial architecture [37,39]. We adopted this experimental
system and used MCF10A ER:HRAS V12 cells transfected
with control or ATG5 siRNA to investigate whether autop-
hagy inhibition promotes oncogenic RAS-induced EMT and
invasion in 3D cultures (Fig. S4C-E). We recovered these cells
from the Matrigel, and examined the protein expression.
ATG5 knockdown in oncogenic RAS-activated MCF10A
cells, achieved a synergistic effect in inducing EMT in 3D
cultures, reflected by a further reduction in CDH1, and
a large increase in ZEB1 expressions levels (Fig. S4C).
Control MCF10A ER:HRAS V12 cells formed single round
acini. Knockdown of ATG5 in control MCF10A ER:HRAS
V12 cells showed no significant effect. Induction of oncogenic
RAS for 24 h before visualization resulted in acini invading
into the Matrigel with short protrusions. When oncogenic
RAS was induced in ATG5-depleted MCF10A cells, almost
all acini produced more and longer protrusions compared to
4-OHT-treated cells (Fig. S4D, E).
These data demonstrate that ATG5 knockdown promotes
cell migration and invasion in RAS-mutated cells in vitro.
Autophagy inhibition promotes oncogenic ras-induced
EMT via the SQSTM1-RELA pathway
One of the key proteins involved in and regulated by autop-
hagy is SQSTM1, which is a critical new player in cancer
[40,41]. It has been suggested that sustained SQSTM1 expres-
sion resulting from autophagic defects is sufficient to activate
the NFKB/NF-κB pathway and promote tumorigenesis [42].
SQSTM1 has also been indicated to be required for efficient
tumorigenesis by oncogenic RAS [10,43]. Importantly, RELA
of the NFKB pathway is one of the key transcription factors
that can directly bind the promoters of SNAI1, SNAI2,
TWIST1, ZEB1 and ZEB2 and induce their expressions
[18,44–46]. These reports suggest a potential role of
SQSTM1 in mediating the biological effects induced by autop-
hagy inhibition in RAS-mutated cells.
In HKe3 ER:HRAS V12 cells, knockdown of ATG3 or
ATG5 in the presence of 4-OHT resulted in SQSTM1 accu-
mulation, concurrent with high levels of ZEB1 (Figure 4
(a, b); Figure S5(a)). In addition, overexpression of exogen-
ous SQSTM1 upregulated ZEB1 in 4-OHT-treated HKe3 ER:
HRAS V12 cells (Figure 4(c)), confirmed by western blot
analysis (Figure 4(d)). These data suggest that excess
SQSTM1 upregulates ZEB1 levels. The role of SQSTM1 in
autophagy inhibition-induced EMT in RAS-mutated cells
was further confirmed by RNAi-mediated depletion of
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Figure 3. Autophagy inhibition promotes oncogenic RAS-induced cell migration and invasion. (a) Scratch wound assay of 4-OHT-treated HKe3 ER:HRAS V12 cells
transfected with control or ATG5 siRNA. Representative images of 4-OHT-treated HKe3 ER:HRAS V12 cells with the indicated treatments at time 0 h or 24 h after the
scratch wound. Wounds have been artificially colored red to aid visualization. Scale bar: 50 μm. (b) Scratch wound assay of control or 4-OHT-treated HKe3 ER:HRAS
V12 cells transfected with control or ATG5 siRNA 24 h after the scratch wound. The graph shows the area of a wound evaluated with ImageJ, and data are mean ± s.
d. n = 4. n.s. P > 0.05, *** P < 0.001. (c) Transwell migration assays in HCT116 cells infected with control or ATG5 shRNA. Cells were stained with crystal violet. Scale
bar: 100 μm. Data are mean ± s.d. n = 3. *** P < 0.001. (d) Transwell Matrigel invasion assays in HCT116 cells infected with control or ATG5 shRNA. Cells were stained
with crystal violet. Scale bar: 100 μm. Data are mean ± s.d. n = 3. *** P < 0.001.
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Figure 4. Autophagy inhibition promotes oncogenic RAS-induced EMT via SQSTM1. (a) Immunofluorescence staining of SQSTM1 (red) and ZEB1 (green), and differential
interference contrast (DIC) images from 4-OHT-treated HKe3 ER:HRAS V12 cells with the indicated treatments. Scale bar: 20 μm. (b) Protein expression of ZEB1, SQSTM1, ATG3,
ATG12–ATG5 and phospho-AKT (p-AKT) in HKe3 ER:HRAS V12 cells with the indicated treatments. TUBB was used as a loading control. (c) 4-OHT-treated HKe3 ER:HRAS V12 cells
were transfected with Cherry-SQSTM1 (red) followed by immunofluorescence staining of ZEB1 (green). TO-PRO-3 (blue) was used to stain nucleic acids. Scale bar: 20 μm. (d)
Protein expression of ZEB1, exogenously expressed Cherry-SQSTM1 and endogenous SQSTM1 in 4-OHT-treated HKe3 ER:HRAS V12 cells transfectedwith control vector or Cherry-
SQSTM1. TUBBwas used as a loading control. (E) Fold change inmRNA levels of ZEB1 and SNAI2 in HKe3 ER:HRAS V12 cells with the indicated treatments.mRNA levels normalized
to GAPDH in control cells were used to set the baseline value at unity. Data are mean ± s.d. n = 3 samples per group. * P < 0.05. ** P < 0.01. *** P < 0.001.
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SQSTM1. As shown in Figure 4(e) and Figure S5(b), autop-
hagy inhibition by knockdown of ATG3 or ATG5 further
increased mutant RAS-induced expression of ZEB1 or
SNAI2, whereas depletion of SQSTM1 partially abolished
their induction, suggesting that SQSTM1 is at least one
major mediator of this effect.
SQSTM1 is necessary for RAS to activate the NFKB path-
way by triggering IKBKB/IκB kinase (part of the IKK com-
plex) through the polyubiquitination of TRAF6 (TNF receptor
associated factor 6) [43,47]. The NFKB pathway regulates
ZEB1 or SNAI2 expression in mammary epithelial cells
[45,46], and is essential for EMT and metastasis in a model
of breast cancer progression [48]. This led us to hypothesize
that SQSTM1 may induce EMT by activating the NFKB
pathway.
To test this, we first assessed NFKB activity using
a reporter assay under different conditions. Oncogenic RAS
activation alone increased NFKB activity approximately
2-fold, while there was a nearly 6-fold increase in NFKB
activity upon ATG5 depletion (Figure 5(a)). Depletion of
SQSTM1 abolished this increase, comparable to the knock-
down of RELA (Figure 5(a)), suggesting that autophagy inhi-
bition in RAS-mutated cells triggers the NFKB pathway via
SQSTM1. This point was further strengthened by the discov-
ery that compared to the staining in oncogenic RAS-
expressing Atg5+/+ or Atg7+/+ tumor cells, RELA was accumu-
lated in the nuclei of oncogenic RAS-expressing atg5−/- or
atg7−/- tumor cells in vivo (Figure 5(b); Figure S6(a)), indicat-
ing that the NFKB pathway is activated in RAS-mutated
tumors when autophagy is inhibited.
Functionally, RELA knockdown abolished the increase in
ZEB1 or SNAI2, and restored CDH1 expression following
autophagy inhibition in RAS-mutated cells (Figure 5(c-e);
Figure S6(b-e)). In HKe3 ER:HRAS V12 cells, ATG3 or
ATG5 knockdown in the presence of 4-OHT dramatically
increased ZEB1 and SNAI2 mRNA levels, whereas RELA
depletion abolished this effect (Figure 5(c); Figure S6(c)),
which was further confirmed by western blot analysis
(Figure 5(d); Figure S6(b)) and immunofluorescence staining
(Figure 5(e)). Depletion of RELA or SQSTM1 was sufficient to
restore the epithelial phenotype of HKe3 cells, demonstrated
by the western blot (Figure 5(d)) and immunofluorescence
staining of CDH1 (Figure 5(e)). Similar results were obtained
from PANC1 cells (Fig. S6D, E). Knockdown of ATG5
induced EMT in PANC1 cells, visible as decreased CDH1
and increased SNAI2 mRNA levels. The depletion of
SQSTM1 or RELA partially or completely abolished the
increase in SNAI2, and restored CDH1 expression.
Finally, we assessed the expression of SQSTM1 and CDH1
in human pancreatic adenocarcinoma where 90% of tumors
harbor KRAS mutations. In TCGA pancreatic adenocarci-
noma Provisional dataset, we found that the SQSTM1 protein
level was not significantly correlated with its mRNA level (Fig.
S7A), which indicates a role for post-transcriptional regula-
tion of SQSTM1 in pancreatic adenocarcinoma, consistent
with the point that the SQSTM1 protein level is mainly
regulated by the autophagic activity [40]. Using this dataset,
we also found that the levels of SQSTM1 protein, but not
mRNA, are significantly inversely correlated with CDH1
mRNA level in this dataset (Figure 6(a), Pearson R = −0.22;
n = 98; P = 0.03; Fig. S7B). Accumulation of SQSTM1 (Fig.
S7C) correlated with loss of CDH1 expression (n = 63;
P = 0.00822) in pancreatic adenocarcinoma (Figure 6(b, c)).
These observations agree with the finding that SQSTM1 accu-
mulation induces EMT. Taken together, these results demon-
strate that autophagy inhibition in RAS-mutated cells
promotes EMT via an SQSTM1-NFKB pathway.
Discussion
Autophagy inhibition is a novel anticancer therapeutic strat-
egy, with approximately 20 ongoing clinical trials employing
this approach, either as monotherapy or in combination with
other agents, in a variety of different cancers (http://www.
cancer.gov/clinicaltrials). The initial interest in autophagy
inhibition as an anticancer therapy was generated by research
revealing that some cancers depend on autophagy for survival
during external stresses such as hypoxia, chemotherapy or
radiotherapy [15,49]. A new rationale for targeting autophagy
has recently been elucidated by several groups, who have
shown that elevated levels of autophagy are required for
cancer cells to evade lethal metabolic stresses and maintain
metabolic homeostasis, particularly in mutant RAS-driven
tumorigenesis [6,8–10,12]. We have previously shown that
autophagic activity helps bypass oncogenic RAS-induced
senescence to allow transformation [11]. It was demonstrated
recently that autophagy is a determinant of carcinoma fate,
and that defects in the autophagic machinery may be
a molecular basis for the occurrence of oncocytomas. Atg7
was deleted concurrently with KRas G12D activation in
mouse models for non-small cell lung cancer. Atg7-deficient
tumors accumulate dysfunctional mitochondria and prema-
turely induce TRP53/p53 and proliferative arrest, which
reduces tumor burden. This is partly relieved by Trp53 dele-
tion. Most interestingly, inflammatory responses are highly
enriched and are responsible for the death of mice with Atg7-
deficient tumors [7].
However, oncogenic RAS can trigger senescence and cell
death via several essential autophagy proteins [50,51], consis-
tent with prior reports that autophagy acts as a tumor sup-
pressive mechanism [49,52,53]. Autophagy inhibition also
significantly accelerates tumor formation in mice containing
oncogenic KRas, but lacking Trp53 [37]. Here, we report
another reason for caution: autophagy inhibition in RAS-
mutated cells induces EMT, which is associated with tumor
invasion.
To inhibit autophagic activity, we depleted ATG3 or ATG5
with RNAi. We observed that autophagy inhibition in RAS-
mutated cells, but not in wild-type RAS-expressing cells, sig-
nificantly reduced CDH1 expression, and dramatically upre-
gulated the expression of several transcriptional repressors of
CDH1, in addition to promoting cell migration and invasion.
Guo et al. reported previously that Atg7 deficiency in tumor-
derived cell lines causes more stromal infiltration in allograft
tumors [7], while stromal infiltration is a predictor of tumor
invasion in several cancer types [54–56]. These results
together suggest that autophagy inhibition may promote
tumor invasion in vitro and in vivo. Although EMT confers
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Figure 5. SQSTM1 accumulation resulting from autophagy inhibition in RAS-mutated cells activates theNFKB pathway to promote EMT. (a) Fold change in NFKB reporter activity
in HKe3 ER:HRAS V12 cells with the indicated treatments. NFKB reporter luciferase readings normalized to Renilla in control cells were used to set the baseline value at unity. Data
are mean ± s.d. n = 3 samples per group. ** P < 0.01. *** P < 0.001. (b) Immunofluorescence staining of RELA (green) in HRas V12-expressing Atg7+/+ or HRas V12-expressing
atg7−/- tumors. TO-PRO-3 (blue) was used to stain nucleic acids. Scale bar: 20 µm. Atg7+/+ or atg7−/- iBMK cells transduced with HRas V12 were subcutaneously injected in nude
mice to form tumors. The graph shows the average nuclear intensity of RELA evaluated with ImageJ, and data are mean ± s.d. n= 3 random fields. ** P < 0.01. (C) Fold change in
mRNA levels of ZEB1 and SNAI2 in HKe3 ER:HRAS V12 cells with the indicated treatments. mRNA levels normalized to GAPDH in control cells were used to set the baseline value at
unity. Data aremean ± s.d. n= 3 samples per group. ** P< 0.01. *** P< 0.001. (d) Protein expression of CDH1, ZEB1, SNAI2, TWIST1, SQSTM1, RELA and ATG12–ATG5 in HKe3 ER:
HRAS V12 cells with the indicated treatments. TUBBwas used as a loading control. (e) Immunofluorescence staining of ZEB1 or CDH1 in HKe3 ER:HRAS V12 cells with the indicated
treatments. Scale bar: 20 μm.
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invasive features that allow cells to disseminate, the reverse
process – mesenchymal-epithelial transition (MET) – is
thought to allow the outgrowth of these cells at distant sites
[37,57–59]. As a result, autophagy inhibition is not necessarily
linked with enhanced metastasis and requires further investi-
gation. To test the true impact of autophagy activity on tumor
metastasis in vivo, a syngenic mouse model with switchable
Atg3 or Atg5 in the presence or absence of oncogenic RAS is
required, because we showed previously that autophagic activ-
ity dictates cellular response to oncogenic RAS-induced senes-
cence [11], while senescent cells are able to secrete cytokines
that will alter the tumor microenvironment, which is likely to
have an impact on the metastatic potential in vivo [60].
Regardless, a number of other existing studies provide sup-
porting evidence for a potential role of autophagy in inhibit-
ing metastasis [29,34]. Rosenfeldt et al. demonstrated that the
autophagy inhibitor hydroxychloroquine significantly acceler-
ates tumor formation in mice containing oncogenic KRas but
lacking Trp53 [34]. Qin et al. showed that inhibition of
autophagy in gastric cancer cells promotes EMT and liver
metastasis [29].
Figure 6. Accumulation of SQSTM1 correlates with negative membrane CDH1 expression in pancreatic adenocarcinoma. (a) The protein expression of SQSTM1 and
mRNA level of CDH1 is significantly inversely correlated in the TCGA pancreatic adenocarcinoma Provisional dataset (Spearman’s R = −0.23, n = 98, P = 0.025). (b)
Adjacent tumor sections from representative cases show SQSTM1 and CDH1 expression in human pancreatic adenocarcinoma. Scale bar: 100 μm. (c) The relationship
between SQSTM1 expression and protein expression of CDH1 was analyzed by Spearman rank correlation test (R = −0.33, n = 63, P = 0.00822). (d) Diagram
summarizing the role of autophagy inhibition in oncogenic RAS-induced EMT (details are provided in the Discussion).
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We went on to confirm that this is achieved by the trigger-
ing of the NFKB pathway through the accumulation of
SQSTM1. Coincidentally, Qiang and colleagues suggested
that autophagy deficiency induces EMT via SQSTM1 through
stabilization of TWIST1 [27]. SQSTM1 is required for effi-
cient tumorigenesis by oncogenic RAS [10,43]. SQSTM1 is
induced by mutant RAS through a mechanism that involves
MAPK/ERK and PI3K, 2 bona fide downstream targets of
RAS, and the AP1 element in the SQSTM1 promoter [43].
Oncogenic RAS requires SQSTM1 to activate the NFKB path-
way [43] for tumorigenesis. In addition, the identification of
SQSTM1 as a new transcriptional target of NFKB is of parti-
cular importance [61]. Therefore, oncogenic RAS activates the
expression of SQSTM1, either directly or via NFKB, to initiate
a feed-forward loop to induce and sustain NFKB activity.
Here, we show that triggering of the NFKB pathway by
SQSTM1 is involved in the EMT induced by autophagy inhi-
bition in RAS-mutated cells. Our data suggest that RAS sig-
nalling may induce SQSTM1 expression [43,61], while also
activating autophagy to reduce its levels. However, inhibition
of autophagy in the presence of a strong RAS signal causes an
accumulation of SQSTM1, resulting in superactivation of the
NFKB pathway, which leads to EMT (Figure 6(d)). Although
it has been shown that activated RAS requires autophagy for
tumorigenesis [8,10], oncogenic RAS-expressing autophagy-
deficient cells can still form tumors in nude mice.
Furthermore, we observed that the NFKB pathway is activated
while CDH1 expression is reduced in these tumors, indicating
that EMT is induced. As a result, autophagy inhibition in
RAS-mutated cancers may help cancer cells detach from
their neighboring cells and invade new sites. We also showed
that depletion of RELA, a key component of the NFKB path-
way, blocks autophagy inhibition-induced EMT in RAS-
mutated cells. NFKB signalling is required for oncogenic RAS-
induced lung tumorigenesis [62,63], and NFKB inhibitors
have therapeutic efficacy in the treatment of lung cancer
[64]. Our report suggests that a combination of autophagy
inhibitors with NFKB inhibitors may therefore be necessary to
treat RAS-mutated cancer (Figure 6(d)).
Materials and methods
Cell culture, reagents and transfections
MDA Panc3, PaCa3, Suit-2, PANC1, HKe3 ER:HRAS V12,
HKh2, HKe3, HCT116 and HaCat cells were cultured in
DMEM (Fisher Scientific UK, 11594446) supplemented with
10% FBS (Invitrogen, 10270106) and antibiotics. MCF10A ER:
HRAS V12 cells were maintained in a 1:1 mixture of DMEM
and Ham’s F12 medium (Fisher Scientific UK, 11524436) sup-
plemented with 5% horse serum (Gibco, 26050088), 20 ng/ml
EGF (Bio-techne, 236-EG), 100 ng/ml cholera toxin (Sigma,
C8052), 10 μg/ml insulin (Sigma, I1882), 500 ng/ml hydrocor-
tisone (Sigma, H0888) and antibiotics. All cells were kept at 37°
C and 10% CO2. For 3D acini cultures, MCF10A ER:HRAS
V12 cells were cultured as previously described [37] on growth
factor-reduced Matrigel (BD Biosciences, 354230). Corning
Cell Recovery Solution was used to recover cells from
Matrigel. TGFB and 4-Hydroxytamoxifen (4-OHT) was pur-
chased from PeproTech (100–21) and Sigma-Aldrich (H6278).
The cherry-SQSTM1 construct was obtained from Prof.
Terje Johansen (University of Tromsø). Transfections were
performed with FuGENE 6 (Promega, E2691), according to
the manufacturer’s instructions.
siRNA oligos against ATG5, ATG3, RELA and SQSTM1 were
purchased from Dharmacon. Sequences are available from
Dharmacon or upon request. As a negative control, we used
siGENOME RISC-Free siRNA (Dharmacon, D-001220–01).
MCF10A ER:HRAS V12 cells were transfected with the indi-
cated siRNA oligos at a final concentration of 37.5 nM using
Lullaby (OZ Biosciences, LL71000), according to the manufac-
turer’s instructions. Other cells were transfected with the indi-
cated siRNA oligos at a final concentration of 35 nM using
Dharmafect 1 reagent (Dharmacon, T-2001–03).
Stable knockdown of human ATG5 was carried out using
pLVX-shRNA-mCherry-Hygro lentiviral expression plasmid.
The ATG5 shRNA plasmid was designed to target the
sequence 5ʹ-CCTGAACAGAATCATCCTTAA-3ʹ.
Western blot analysis
Western blot analysis was performed with lysates from cells or
tissues with urea buffer (8 M urea [Sigma, U5378], 1 M thiourea
[Sigma, T8656], 0.5% CHAPS [Fisher Scientific, 11461851],
50 mMDTT [Fisher Scientific UK, 10375600], 24 mM spermine
[Sigma, 85,590]). Primary antibodies were from: Santa Cruz
Biotechnology (ACTB/β-actin, sc-47778; ZEB1, sc-25388;
ZEB2, sc-48789; CDH1, sc-21791; SNAI2, sc-10436), Abcam
(TUBB/β1-tubulin, ab6046; GAPDH, ab9385), Cell Signaling
Technology (ATG5, 2630; ATG3, 3415; LC3, 3868; phospho-
AKT, 9271; AKT, 4685; phospho-MAPK, 4370; SNAI1, 3879;
SNAI2, 9585; RELA, 8242; TWIST1, 46702; phospho-Smad2,
3104; Smad2, 5339), Progen Biotechnik GmbH (SQSTM1,
GP62-C), BD Transduction Laboratories (CDH1, 610405;
SQSTM1, 610833). Signals were detected using an ECL detection
system (GE Healthcare, RPN2108) or Odyssey imaging system
(LI-COR, United States), and evaluated by ImageJ 1.42q software
(National Institutes of Health, United States).
Quantitative reverse transcription-PCR
The real-time RT-PCR was performed using gene-specific pri-
mers (QuantiTect Primer Assays, Qiagen) for CDH1, VIM,
ZEB1/2, SNAI1/2, TWIST1, or GAPDH with QuantiTect SYBR
Green RT-PCR Kits (Qiagen, 204243). Relative transcript levels
of target genes were normalized to GAPDH mRNA levels.
Luciferase reporter assay
HKe3 ER:HRAS V12 cells were transfected with the indicated
siRNAs for 48 h in 24-well plates, followed by 24-h transfec-
tion with 250 ng of NFKB reporter and 10 ng of phRL-CMV
(Promega, E2261), which constitutively expresses the Renilla
luciferase reporter. One day before the measurement of luci-
ferase activity 100 nM 4-OHT was added. Finally, the
896 Y. WANG ET AL.
transcription assay was carried out using the Dual-luciferase®
reporter assay system (Promega, E1960) following the manu-
facturer’s protocol.
Wound-healing migration, transwell migration and
matrigel invasion assays
The wound-healing migration assays were done in conjunc-
tion with siRNA transfections in control or 4-OHT-treated
HKe3 ER:HRAS V12 cells. Seventy-two h after siRNA trans-
fections, confluent monolayers of cells were wounded with
a p20 pipette tip (time 0). Phase-contrast images were taken
using an Olympus inverted microscope at time 0 h or 24 h
after the scratch wound. For the Transwell migration assay,
Transwell membranes (8-μm pore size, 6.5-mm diameter;
Corning Costar, 3422) were used. The bottom chambers of
the Transwell were filled with migration-inducing medium
(with 50% FBS). The top chambers were seeded with
1.5 × 105 live serum-starved control or ATG5 shRNA
HCT116 cells per well. After 48 h, the filters were fixed with
4% paraformaldehyde for 10 min at room temperature; sub-
sequently, the cells on the upper side of the membrane were
scraped with a cotton swab. Similar inserts coated with
Matrigel (Corning, 354480) were used to determine invasive
potential in invasion assays. Filters were stained with crystal
violet for light microscopy. Images were taken using an
Olympus inverted microscope and migratory cells were eval-
uated by ImageJ 1.42q software (National Institutes of Health,
United States).
Immunofluorescence
Cells were fixed in 4% PBS (Fisher Scientific UK, 12579099)-
paraformaldehyde for 15 min, incubated in 0.1% Triton-
X-100 (Fisher Scientific UK, 11471632) for 5 min on ice,
then in 0.2% fish skin gelatin (Sigma, G7041) in PBS for 1
h and stained for 1 h with an anti-CDH1 (Santa Cruz
Biotechnology, sc-21791; 1:100), anti-ZEB1 (Santa Cruz
Biotechnology, sc-25388; 1:100), anti-LC3 (Cell Signaling
Technology, 3868; 1:100) or anti-SQSTM1 (Progen
Biotechnik GmbH, GP62-C; 1:300) antibody. Protein expres-
sion was detected using Alexa Fluor 488 or 546 (1:400; Fisher
Scientific UK, 10256302,10789154,10729174,10002502,10717
474) for 20 min. TO-PRO-3 (Invitrogen, T3605: 1:1000) was
used to stain nucleic acids. Rhodamine-phalloidin (Molecular
Probes, R415) was used to visualize filamentous actin
(F-actin). For immunofluorescence staining of 3D cultures
from MCF10A ER:HRAS V12 cells, acini were fixed with 4%
paraformaldehyde for 40 min, permeabilized in 0.5% Triton
X-100 for 10 min on ice and stained with Rhodamine-phalloi-
din for 1 h at room temperature. Acini were counterstained
with DAPI. For tissue immunofluorescence staining, rehy-
drated paraffin-embedded sections were microwaved in
10 mM sodium citrate buffer (pH 6) to unmask the antigen,
washed with PBS, and incubated overnight with the primary
antibody at 4°C, followed by Alexa Fluor 488 or 546 (1:400;
Fisher Scientific UK, 10256302,10789154,10729174,10002502)
secondary antibody for 60 min at room temperature. The
sections were incubated with primary antibodies against
CDH1 (Santa Cruz Biotechnology, sc-21791; 1:200), or
RELA (Santa Cruz Biotechnology, sc-372; 1:200). When
grown in nude mice, nontumorigenic baby mouse kidney
epithelial (iBMK) cells transduced with HRas V12 formed
tumors [10]. Oncogenic Ras (HRas V12)-expressing atg5−/-
or atg7−/- iBMK tumor sections and oncogenic Ras (HRas
V12)-expressing Atg5+/+ or Atg7+/+ iBMK tumor sections
were obtained from Prof. Eileen White (Rutgers Cancer
Institute of New Jersey), described in an earlier publication
in detail [10]. Samples were observed using a confocal micro-
scope system (LSM 510 or LSM 710; Carl Zeiss, Germany).
Acquired images were analyzed using Photoshop (Adobe
Systems, United States) according to the guidelines of the
journal.
Immunohistochemical analysis
A pancreatic tissue microarray (reference no. HPan-Ade
150CS-01), consisting of pancreatic adenocarcinoma and
matched normal adjacent pancreatic tissue, was obtained
from Shanghai Outdo Biotech Co., Ltd. (Shanghai, China).
Sections were de-waxed, rehydrated and incubated with 3%
hydrogen peroxide in methanol to block endogenous perox-
idase activity (10 min). Sections were then blocked with
normal goat serum (Fisher Scientific UK, 11819220) and
incubated overnight at 4°C with a primary antibody against
CDH1 (1:250: Cell Signaling Technology, 14472) or SQSTM1
(1:200: Cell Signaling Technology, 88588), followed by the
biotinylated secondary antibody (Vector Labs, BA-1400, BA-
1000; 1:250) for 40 min at room temperature. The staining
reaction was worked up using the Vector Elite ABC kit
(Vector Labs, PK-7200) and counterstained with haematoxy-
lin. The staining intensity was graded as follows: No staining
(0), weak (1), moderate (2) and intense staining (3). Samples
that could not be graded were scored as ‘not applicable’. For
each sample, membrane expression of CDH1 was determined
as the average score of the sample spot, and then further
subgrouped into negative (score 0) or positive (scores 1–3);
while SQSTM1 accumulation present or absent was deter-
mined by comparing the pancreatic adenocarcinoma to the
matched normal adjacent pancreatic tissue. Statistical analysis
was undertaken in SPSS. The relationship between SQSTM1
accumulation and membrane expression of CDH1 was ana-
lyzed using the Spearman rank correlation test.
TCGA analysis
Information on CDH1 mRNA expression and SQSTM1 pro-
tein expression was examined using The Cancer Genome
Atlas (TCGA) http://www.cbioportal.org/index.do [65,66].
Statistical analysis was undertaken in SPSS. The relationship
between SQSTM1 protein expression and SQSTM1 or
CDH1 mRNA expression was analyzed using the Spearman
rank correlation test.
Statistical analysis and repeatability of experiments
Each experiment was repeated at least twice. Unless otherwise
noted, data are presented as mean ± s.d., and a two-tailed,
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unpaired Student’s t-test was used to compare 2 groups for
independent samples. P < 0.05 was considered statistically
significant.
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